Yocca Frank (CIK 1733272) reported 15 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-17). Recent activity: Buy BTAI (35 shares), Buy BTAI (17,500 shares), Sell BTAI (6,845 shares), Buy BTAI (9,000 shares), Buy BTAI (33 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 35 | $0 |
| 2026-05-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 17,500 | $0 |
| 2026-05-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Sell | 6,845 | $7,427 |
| 2026-05-07 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 9,000 | $0 |
| 2026-03-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 33 | $0 |
| 2026-03-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 35 | $0 |
| 2025-12-15 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 33 | $0 |
| 2025-12-15 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 35 | $0 |
| 2025-09-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 33 | $0 |
| 2025-09-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 35 | $0 |
| 2025-07-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 4,375 | $0 |
| 2025-06-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 33 | $0 |
| 2025-06-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 35 | $0 |
| 2025-03-17 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 31 | $0 |
| 2025-03-17 | BioXcel Therapeutics, Inc. (BTAI) | Chief Scientific Officer | Buy | 34 | $0 |
Source: SEC Form 4 filings · as of 2026-06-17